Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer.
BACKGROUND
Oxaliplatin, a third-generation platinum derivative is commonly used for the treatment of colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients.


METHODS
We present a case of a female patient with locally advanced unresectable pancreatic cancer who developed hearing loss after receiving oxaliplatin and gemcitabine. The dose of oxaliplatin was reduced but continued due to clinical benefit and radiological response.


CONCLUSIONS
To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity. Ototoxicity seems to be a rare complication of oxaliplatin therapy. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients's clinical symptoms.
Department of Hematology/Oncology and Experimental Therapeutics, Tufts University School of Medicine. Boston, MA, USA. wsaif@tuftsmedicalcenter.org.
Sun Young
SY
Oh
Nawal
N
Wasif
Marie Carmel
MC
Garcon
Gladys
G
Rodriguez
Muhammad Wasif
MW
Saif
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects; D001299:Audiometry / Q000379:methods; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin